Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.

Abstract

The interest in better understanding the immune-microenvironment and tumor cells crosstalk, recently leads to focus on immune checkpoints role, notably on PD-1/PD-L1 axis. The current backdrop concerning cancer immunotherapy is constantly evolving and new biomarkers still need to be granted in this dynamic context. This review tries to get lights on PD-L1 complex scenario mainly focusing on troubling issues in assessing this marker in daily practice. It's still necessary to look deeper into this matter in order to make easier the pathologists-oncologist interaction.

• Authors: M Callea, F Pedica, C Doglioni
• Journal: Pathologica (Pathologica) Vol. 108 Issue 2 Pg. 48-58 (Jun 2016) ISSN: 0031-2983 [Print] Italy
• PMID: 28195250 (Publication Type: Journal Article, Review)
• Copyright: © Copyright Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology.

Chemical References

• Antineoplastic Agents
• B7-H1 Antigen
• Biomarkers, Tumor
• CD274 protein, human
• PDCD1 protein, human
• Programmed Cell Death 1 Receptor

Topics

• Antineoplastic Agents (therapeutic use)
• Apoptosis (drug effects)
• B7-H1 Antigen (antagonists & inhibitors, immunology, metabolism)
• Biomarkers, Tumor (antagonists & inhibitors, immunology)
• Humans
• Immunohistochemistry
• Immunotherapy (methods)
• Neoplasms (drug therapy, immunology, metabolism, pathology)
• Pathologists
• Patient Selection
• Predictive Value of Tests
• Programmed Cell Death 1 Receptor (antagonists & inhibitors, immunology, metabolism)
• Reproducibility of Results
• Signal Transduction (drug effects)
• Tumor Microenvironment